Science

Compass pathways’ phase 2B… breakthrough therapy designation by the US FDA in late 2018… delivers mixed results

…a 35-percent response rate and a 5-percent SAE rate means for every seven patients positively responding to the treatment, one person will experience serious negative outcomes… these serious adverse events included suicidal ideation and suicidal behavior.

Five patients (6.3 percent) in the 25-mg group and six patients (8 percent) in the 10-mg group experienced at least one serious adverse event in the follow-up period after the psilocybin treatment. This compared to just one serious adverse event reported in the 1-mg placebo group.

Original Article (New Atlas):
Largest psychedelic therapy trial to date delivers mixed results
Artwork Fair Use: Beeblebrox

Psychology

…tripping solo

Spirituality

LSD… benefits…

Psychology

…salvinorin…

Anthropology

There will be oil

Anthropology

Cannabis goes green

Psychology

Home grow…

Psychology

…for macrodosing

Politics

First, it was weed…

Politics

Manufacturing…

Spirituality

…the Mushroom

Politics

Oregon psilocybin…

Science

What is kratom…?

Politics

SITSA … stopped

Politics

Grassy Globes

Politics

Weed wages water war

Politics

Big acid

Politics

Can Kratom be patented?

Science

Kratom LD-50 Stats

Science

Rolling in the deep

Science

The Peace Drug